CHAPMAN STEVEN M
Known title: DirectorCIK: 0001238885
Associated companies
Transaction History
| AXTA | ▲ Buy | Option Exercise | 2,658 | — | 6/6/2024 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 6,711 | — | 2/28/2024 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 6,939 | — | 2/15/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 7,208 | — | 3/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
UBS Cuts Axalta Price Target to $36, Maintains Neutral Rating
UBS lowered its price target for Axalta to $36 while keeping a neutral stance. The company also announced the date for its third-quarter 2026 earnings call. These updates provide new context as Axalta trades near its 52-week low, with the stock currently sitting above a key support level.
UBS Cuts Axalta Price Target to $36, Maintains Neutral Rating. UBS lowered its price target for Axalta to $36 while keeping a neutral stance. The company also announced the date for its third-quarter 2026 earnings call. These updates provide new context as Axalta trades near its 52-week low, with the stock currently sitting above a key support level.